Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MOLN, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| [212Pb]Pb-MP0712 | Large Cell Neuroendocrine Carcinoma | Phase 1/2 · NCT07278479 | Recruiting |
| FAP/CD40-targeting DARPin MP0317 | Advanced Biliary Tract Carcinoma | Phase 2 · NCT07036380 | Recruiting |
| Lutetium Lu 177-DOTA-EB-TATE | Neuroendocrine Tumors | Phase 1 · NCT05475210 | Completed |
| Interleukin-3 Receptor Subunit Alpha | Leukemia | Phase 1 · NCT05673057 | Completed |
| Anti-CD33/CD123/CD70 DARPin CD3 Engager MP0533 | Leukemia | Phase 1 · NCT05673057 | Completed |
Also used in these trials (approved or third-party drugs, not MOLN's own candidates): Gemcitabine Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MOLN holds $57.5M in cash and short-term investments and burns about $11.7M/quarter from operations, an estimated runway of 14.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 28 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MOLN files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MOLN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →